Hematologic Oncology | Specialty

Role of Dual Targeted Therapy in AML

February 8th 2021

Sequencing of FLT3 Inhibitors in AML

February 8th 2021

Perales Examines the Impact of COVID-19 on Recipients of Cellular Therapies for Cancer

February 6th 2021

February 5, 2021 - Following stem cell transplant or treatment with CAR T-cell therapies, patients with hematologic malignancies and coronavirus disease 2019 tend to have favorable outcomes, especially if they are diagnosed in complete remission and further out from their cell infusion.

Dr. Abramson on the FDA Approval of Liso-Cel in Refractory Large B-Cell Lymphoma

February 5th 2021

Jeremy S. Abramson, MD, discusses the FDA approval of lisocabtagene maraleucel in refractory large B-cell lymphoma.

FDA Approves Umbralisib for Marginal Zone Lymphoma, Follicular Lymphoma

February 5th 2021

February 5, 2021 - The FDA has granted an accelerated approval to umbralisib for the treatment of select patients with relapsed/refractory marginal zone lymphoma and relapsed/refractory follicular lymphoma.

FDA Approves Liso-Cel for Refractory Large B-Cell Lymphoma

February 5th 2021

February 5, 2021 - The FDA has approved lisocabtagene maraleucel for the treatment of adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least 2 other types of systemic treatment.

R/R DLBCL: Second-Line Treatment Options

February 5th 2021

DLBCL: Treating Patients Following Relapse on Frontline Therapy

February 5th 2021

Selinexor Approved in Israel for Multiple Myeloma, DLBCL

February 4th 2021

February 4, 2021 — The Israeli Ministry of Health has approved selinexor for the treatment of patients with multiple myeloma or diffuse large B-cell lymphoma.

Gilteritinib Receives Conditional Approval in China for FLT3+ AML

February 4th 2021

February 4, 2021 - The China National Medical Products Administration has granted a conditional approval to gilteritinib for use in adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation detected by a validated test.

2020 Approvals Expand Access to Care for Patients Across Tumor Types

February 4th 2021

In a year marked by collaboration and innovation, therapeutic developments in oncology care once again dominated the novel drug approvals in 2020.

Surge of New Drugs Fuels Optimism in Pediatric Oncology

February 4th 2021

The landscape for pediatric oncology drugs expanded dramatically last year, with 8 new drugs or indications specifically approved for children compared with just 47 for treatment and supportive care products from the early 1950s through 2019.

Managing MRD-Positive Acute Lymphoblastic Leukemia

February 4th 2021

Treatment of Acute Lymphoblastic Leukemia in the Community Setting

February 4th 2021

A Look at the ELEVATE-TN and ASCEND Trials

February 3rd 2021

Dr Stilgenbauer explains the ELEVATE-TN and ASCEND clinical trials; Dr Brown highlights the adverse effects seen with acalabrutinib.

Acalabrutinib in the Treatment of Chronic Lymphocytic Leukemia

February 3rd 2021

Experts provide insight on the use of acalabrutinib in treating chronic lymphocytic leukemia.

Clinical Trials With BTK Inhibitors in Chronic Lymphocytic Leukemia

February 3rd 2021

Dr Brown provides a brief overview of data available that support the use of Bruton’s tyrosine kinase inhibitors in treating chronic lymphocytic leukemia; Dr Stilgenbauer comments on mitigating and managing adverse effects in the treatment of chronic lymphocytic leukemia.

BTK Inhibitors in Treatment of Chronic Lymphocytic Leukemia

February 3rd 2021

Dr Ghia provides an in-depth conversation on the use of Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia.

Individualized Induction Therapy for NDMM

February 3rd 2021

Approaching Early Treatment of High-Risk SMM

February 3rd 2021